Technology evaluation: ABT-510, Abbott

Curr Opin Mol Ther. 2004 Aug;6(4):451-7.

Abstract

ABT-510 is a small peptide thrombospondin-1 mimetic angiogenesis inhibitor under development by Abbott Laboratories for the potential treatment of solid tumors. ABT-510 is undergoing phase II clinical trials.

Publication types

  • Evaluation Study

MeSH terms

  • Amino Acid Sequence
  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / genetics
  • Angiogenesis Inhibitors / metabolism*
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / metabolism*
  • Antineoplastic Agents / therapeutic use
  • Clinical Trials, Phase II as Topic
  • Humans
  • Mice
  • Oligopeptides / adverse effects
  • Oligopeptides / genetics
  • Oligopeptides / metabolism*
  • Oligopeptides / therapeutic use
  • Thrombospondin 1 / chemistry

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt
  • Oligopeptides
  • Thrombospondin 1